Jill Tyler
Adult Health · Haddon Heights, NJNPI 1952374589
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 397 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 68.1% of it on its own, with 26 other manufacturers making up the rest. Among adult health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 397 payments — averaging $31.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$8K
- Novartis$645
- E.r. Squibb & Sons, L.L.C.$593
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$566
- AstraZeneca$443
- Boehringer Ingelheim$260
- plus $1K from 21 others
What the payments were for
- Food & beverage$12,453100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 202 | $8,478 |
| Novartis | 70 | $645 |
| E.r. Squibb & Sons, L.L.C. | 25 | $593 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $566 |
| AstraZeneca | 11 | $443 |
| Boehringer Ingelheim | 3 | $260 |
| Pfizer | 14 | $254 |
| Johnson & Johnson | 9 | $226 |
| Esperion Therapeutics, Inc. | 3 | $139 |
| Cvrx, Inc. | 1 | $137 |
| Merck | 7 | $100 |
| Amarin Pharma, Inc. | 7 | $95 |
| Impulse Dynamics (USA) Inc. | 3 | $81 |
| Daiichi Sankyo Inc. | 4 | $60 |
| Lexicon Pharmaceuticals, Inc. | 3 | $51 |
| Bayer | 3 | $50 |
| Amgen | 3 | $43 |
| W. L. Gore & Associates, Inc. | 3 | $39 |
| Actelion Pharmaceuticals US, Inc. | 2 | $30 |
| Biogen | 1 | $27 |
| Novo Nordisk | 2 | $27 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Chiesi USA, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$1,237
- Fortify Assura, Ellipse ICD$355
- Fortify Assura$251
- JARDIANCE$245
- CAMZYOS$233
- Confirm Rx$151
- Barostim Neo System$137
- AMPLATZER$128
- XIENCE SIERRA$128
- NEXLIZET$125
- NEXLETOL$125
- ENSITE$123
- ELIQUIS$111
- XARELTO$110
- Perclose ProStyle$106
- FARXIGA$103
How this compares
$12,453 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 216 | $266,992 |
| XareltoRivaroxaban | 72 | $89,311 |
| EntrestoSacubitril/Valsartan | 19 | $36,794 |
| Repatha SureclickEvolocumab | 22 | $24,927 |
| FarxigaDapagliflozin Propanediol | 17 | $19,582 |
| Metoprolol Succinate | 280 | $4,278 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 22 | $3,037 |
| Ezetimibe | 54 | $2,231 |
| Atorvastatin Calcium | 131 | $2,163 |
| Valsartan | 52 | $1,820 |
| Rosuvastatin Calcium | 96 | $1,695 |
| Carvedilol | 132 | $1,527 |
| Amlodipine Besylate | 142 | $1,309 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 38 | $1,299 |
| Lisinopril | 103 | $1,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $254 | $266,992216 claims |
| Johnson & JohnsonXarelto | $226 | $89,31172 claims |
| NovartisEntresto | $645 | $36,79419 claims |
| AstraZenecaFarxiga | $443 | $19,58217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.
Other adult health in Haddon Heights
- June HalperHackensack$358K
- Kara SaggiomoCamden$127K
- Entela AhmetiPomona$75K
- Phyllis McKiernanHackensack$72K
- Denise ForceMiddletown$71K
- Kathleen SenecaHillsborough$64K
- Diane AndresenNorthvale$60K
- Dana BeenstockFreehold$51K
- Phyllis DudaCamden$46K
- Anthony WalkoWestwood$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.